Back to search

Poland· PL-100510022

Amifampridine Medical Valley

A amifampridine product containing amifampridinum, registered in Poland by Medical Valley Invest AB. The same ATC class is registered in 16 of our 19 countries.

ATC N07XX05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAmifampridine Medical ValleyATCN07XX05REGISTER NO.PL-100510022PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Amifampridine is registered in 16 of 19 countries.

Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Amifampridine · ATC N07XX05

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of amifampridine costs, country by country.

Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Amifampridine · price per daily dose (40 mg)

USD · FX 28 Sept 2026

  • FR France$3657.38
  • CH Switzerland$75.59
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Amifampridinum
Manufacturer
Medical Valley Invest AB
Country
Poland (PL)
ATC code
N07XX05
ATC class
Amifampridine
Defined daily dose
40 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991605445

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for amifampridine.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Amifampridine · interactions on record

82 records

  • 4 severe
  • 78 moderate

Most severe, free to view

  • BupropionN06AX12severe
  • BupropionN07BA02severe
  • IohexolV08AB02severe
  • IopamidolV08AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Amifampridine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amifampridine products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Germany · Amifampridin Accord, Amifampridin Amarox
  • France · Amifampridine Amarox, Amifampridine Biogaran
  • Hungary · Amifampridine Accord
  • Iceland · Amifampridine Serb, Firdapse
  • Italy · Amifampridina Accord
  • Liechtenstein · Amifampridine Serb, Firdapse
  • Netherlands · Amifampridine Accord, Amifampridine Amarox
  • Norway · Amifampridin Medical Valley, Amifampridine Accord
  • Portugal · Amifampridina Accord, Amifampridina Generis
  • Slovenia · Amifampridin Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bb98dedf-eecc-4ff5-9d2f-abfd9089f1a2
GET /v1/drugs/bb98dedf-eecc-4ff5-9d2f-abfd9089f1a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "05909991605445 ¦ Rpz ¦ 167747\n100 tabl.",
  "substance": "Amifampridinum 10 mg",
  "common_name": "Amifampridinum",
  "pl_product_id": "100510022",
  "pozwolenie_nr": "29814",
  "auth_procedure": "DCP",
  "authorisation_validity": "2031-07-09"
}

See everything about amifampridine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.